tirzepatide and semaglutide GLP-1 drugs such as are transforming obesity and diabetes care in India, but experts warn that improper use could lead to significant muscle loss. A new India-specific consensus highlights Tirzepatide as Compared with Semaglutide

Our care team believes its just as important to help patients maintain their weight as it is to help them lose weight in the first place

Can we give them information to help with that decision? Such tools could have immediate clinical applications

And because retatrutide is not FDA-approved, there is no standardized dosing schedule, no prescription oversight, and no medical supervision

In January, U.S

Real-world effectiveness Studies examining real-world outcomes show that results are typically somewhat lower than in clinical trials but still significant: A 2025 Cleveland Clinic study found average weight loss of 10-15% in routine clinical practice (compared to 15-22% in trials)